Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | +18.73% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.63 | N/A | +18.73% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management appears cautiously optimistic about the company's direction. They emphasized their commitment to advancing their pipeline, although specific revenue guidance was not provided.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in research and development as a priority.
Nektar Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 2.67%. The absence of revenue figures and guidance may leave some investors cautious, but the EPS beat indicates potential operational improvements. The management's focus on R&D suggests they are prioritizing long-term growth despite current uncertainties.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WEC ENERGY GROUP INC
Aug 5, 2019